0001140361-17-008973.txt : 20170224
0001140361-17-008973.hdr.sgml : 20170224
20170224100516
ACCESSION NUMBER: 0001140361-17-008973
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160401
FILED AS OF DATE: 20170224
DATE AS OF CHANGE: 20170224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kramer Robert
CENTRAL INDEX KEY: 0001380956
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 17635133
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4/A
1
doc1.xml
FORM 4/A
X0306
4/A
2016-04-01
2016-04-05
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380956
Kramer Robert
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG
MD
20879
0
1
0
0
EVP, Corporate Services Divisi
Common Stock
2016-04-01
4
M
0
11531
14.41
A
91607
D
Common Stock
2016-04-01
4
S
0
11531
35.49
D
80076
D
Common Stock
2016-04-01
4
M
0
3939
14.67
A
84015
D
Common Stock
2016-04-01
4
S
0
3939
35.74
D
80076
D
Common Stock
2016-04-01
4
M
0
17354
28.09
A
97430
D
Common Stock
2016-04-01
4
S
0
17354
35.48
D
80076
D
Common Stock
2016-04-01
4
M
0
5503
29.00
A
85579
D
Common Stock
2016-04-01
4
S
0
5503
35.66
D
80076
D
Common Stock
2016-04-01
4
S
0
445
35.93
D
79631
D
Common Stock
2016-04-01
4
S
0
1855
35.80
D
77776
D
Common Stock
2016-04-01
4
S
0
2945
35.73
D
74831
D
Stock Option
14.41
2016-04-01
4
M
0
11531
0
A
2019-11-04
Common Stock
11531
11531
D
Stock Option
14.67
2016-04-01
4
M
0
3939
0
A
2020-03-11
Common Stock
3939
3940
D
Stock Option
28.09
2016-04-01
4
M
0
17354
0
A
2021-03-10
Common Stock
17354
34708
D
Stock Option
29.00
2016-04-01
4
M
0
5503
0
A
2022-03-09
Common Stock
5503
27514
D
These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016.
Consists of an option granted under the company's stock incentive plan on November 5, 2012.
Consists of an option granted under the company's stock incentive plan on March 12, 2013.
Consists of an option granted under the company's stock incentive plan on March 11, 2014.
Consists of an option granted under the company's stock incentive plan on March 10, 2015.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $36.34, inclusive.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.37 to $36.32, inclusive.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.07 to $36.35, inclusive.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.12 to $36.42, inclusive.
Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.00, inclusive.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.13, inclusive.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.32, inclusive.
The option vested in three equal installments in November 2013, 2014 and 2015.
The option vest in three equal installments in March 2014, 2015 and 2016.
The option vest in three equal installments in March 2015, 2016 and 2017.
The option vest in three equal installments in March 2016, 2017 and 2018.
EXPLANATORY NOTE: The sole purpose of this amendment to the Form 4 is to denote that the execution of all of the sale transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 29, 2016.
/s/ Eric Burt, attorney-in-fact
2017-02-24